July 29, 2026 Becton Dickinson & Co Launches Semaglutide Therapy in Brazil in Partnership with EMS Becton Dickinson has teamed up with EMS to launch a new semaglutide therapy in Brazil, aimed at improving access to treatments for chronic diseases like obesity and type 2 diabetes. Utilizing BD's innovative Vystra™ Injection Pen, this partnership focuses on patient-centered delivery solutions.
July 28, 2026 Becton, Dickinson & Co. Declares Quarterly Dividend Amidst Continued Innovation Becton Dickinson announces a quarterly dividend of $1.05 per share, reaffirming its commitment to shareholder value. The company continues to lead in medical technology innovation, enhancing healthcare outcomes globally.
July 22, 2026 Becton Dickinson Announces Retirement of Executive Mike Garrison Becton Dickinson has announced the retirement of Dr. Mike Garrison, a pivotal leader in the company, effective October 2, 2026. Garrison's contributions over two decades have significantly shaped BD's growth and transformation. The company is now searching for his successor to ensure a smooth transition.
July 09, 2026 Becton Dickinson & Co Set to Announce Third Quarter Financial Results Becton Dickinson & Co. is set to announce its Q3 earnings on August 6, 2026. The webcast will cover financial performance and ongoing strategic initiatives as BD focuses on innovation in healthcare.
June 23, 2026 BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract by Vizient, recognizing its potential to improve central line insertion procedures. The all-in-one system simplifies processes, enhances safety, and is expected to significantly impact healthcare delivery.
May 21, 2026 BD Expands Urology Portfolio with the Launch of Elyra™ Thulium Fiber Laser System BD has launched the Elyra™ Thulium Fiber Laser System to improve kidney stone care in urology. Featuring advanced technology for efficient stone dusting and customizable settings, it aims to enhance procedural workflows and patient outcomes.
May 18, 2026 Becton Dickinson & Co Appoints Peter Menziuso as EVP and President of BD Interventional Becton Dickinson has appointed Peter Menziuso as EVP and President of BD Interventional, effective June 1, 2026. With over 30 years of experience, Menziuso aims to drive growth and innovation within the company, focusing on operational excellence and customer value.
May 07, 2026 Vitor Roque Appointed Chief Financial Officer of Becton Dickinson & Co Becton Dickinson has appointed Vitor Roque as Chief Financial Officer, effective May 2026. Roque, who served as interim CFO, brings 25 years of experience and a strong vision for sustainable growth in the healthcare sector.
May 07, 2026 Becton Dickinson & Co Reports Strong Q2 Results for Fiscal 2026 Becton Dickinson & Co reported a 5.2% increase in Q2 2026 revenues, driven by strong performance across business segments and innovative product launches. The company updated its EPS guidance, reflecting confidence in its operational strategy and market position.
May 05, 2026 BD Partners with Wellstar to Enhance Medication Management with AI BD has partnered with Wellstar Health System to revolutionize medication management through advanced AI technology. This collaboration aims to improve patient safety and streamline workflows by integrating innovative dispensing and infusion systems.
April 30, 2026 BD Achieves Excellence in Employee Well-Being, Earning Top Industry Recognition Becton, Dickinson and Company (BD) has been recognized for its outstanding employee well-being programs, earning accolades for its holistic approach to health. This recognition reflects BD's commitment to diversity, inclusion, and corporate sustainability, positioning the company for future success in the medical technology sector.
April 29, 2026 BD Launches Revolutionary CentroVena One™ Insertion System to Enhance Patient Safety Becton, Dickinson and Company (BD) has launched the revolutionary CentroVena One™ Insertion System, which streamlines central line insertion and enhances patient safety. This all-in-one device reduces procedural steps by 30% and minimizes risks associated with traditional methods, marking a significant advancement in vascular access technology.
April 28, 2026 BD Declares Quarterly Dividend, Reinforcing Commitment to Shareholder Value Becton, Dickinson and Company has declared a quarterly dividend of $1.05 per share, reaffirming its commitment to shareholder value. This decision reflects BD's strong financial health and operational efficiency, positioning the company favorably in the medical technology sector.
April 27, 2026 Becton Dickinson & Co to Present at Upcoming Health Care Conference Becton Dickinson & Co will present at the Bank of America Securities Health Care Conference on May 12, 2026, offering insights into their healthcare innovations. A live webcast will be available for investors, reflecting BD's commitment to transparency and health advancement.
April 16, 2026 BD Recognized for Excellence in Transparency, Resiliency, and Partnership Becton, Dickinson and Company (BD) has been recognized by HIRC for its outstanding performance in Transparency, Resiliency, and Partnership. These awards reflect BD's dedication to enhancing supply chain efficiency and delivering high-quality patient care through strong collaborations and operational excellence.
April 09, 2026 BD Set to Reveal Second Quarter Financial Results for Fiscal 2026 Becton, Dickinson and Company will host a webcast on May 7, 2026, to discuss its financial results for Q2 2026. Investors can access insights into BD's performance and strategic initiatives following the release of key financial documents.
April 09, 2026 Becton Dickinson & Co Announces Retirement of Executive Vice President Rick Byrd Becton Dickinson & Co has announced the retirement of Rick Byrd, an executive vice president with nearly 25 years at the company. Byrd's leadership has significantly impacted BD's operations and innovation, especially during the COVID-19 pandemic. The company is set to name a successor to ensure a smooth transition.
April 09, 2026 Becton Dickinson & Co. Enhances Nighttime Comfort for Women with New Findings on PureWick® System Becton Dickinson's PureWick® Urine Collection System improves nighttime comfort for women with urinary incontinence, enhancing sleep quality and independence. A recent clinical study highlights its user-friendly design and effectiveness in managing urine capture.
April 08, 2026 BD Unveils Liverty™ TIPS Stent Graft: A New Era in Portal Hypertension Treatment Becton Dickinson has launched the Liverty™ TIPS Stent Graft, designed to improve treatment for portal hypertension and cirrhosis. This CE Mark-approved device offers adjustable diameters and diverse lengths for personalized patient care, marking a significant advancement in medical technology.
April 07, 2026 BD Launches HemoSphere Stream™ Module: A Game-Changer in Noninvasive Blood Pressure Monitoring BD's HemoSphere Stream™ Module is a groundbreaking noninvasive device designed to provide real-time blood pressure monitoring, improving patient safety, especially in surgical settings. Coupled with the VitaWave™ Plus Finger Cuff, it ensures accurate hemodynamic data for better clinical decision-making.
April 01, 2026 BD Launches AI-Enabled Medication Dispensing System to the European Market BD has introduced its BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform to the European market, revolutionizing medication management with AI. This launch focuses on improving efficiency and security, enabling clinicians to concentrate on patient care.
March 05, 2026 BD Advances Iliac Artery Treatment Across the European Union BD has received CE Marking for its Revello™ Vascular Covered Stent, designed to treat complex iliac artery diseases in patients with peripheral artery disease (PAD). The stent's innovative features aim to improve patient outcomes while minimizing complications during procedures.
March 02, 2026 BD Introduces Revolutionary Surgiphor™ 1000mL for Enhanced Surgical Safety BD has launched the Surgiphor™ 1000mL, a groundbreaking antimicrobial irrigation system designed to enhance surgical safety. This innovative solution integrates into existing workflows, providing a sterile, ready-to-use option that streamlines operations and supports healthcare teams in delivering better patient care.
February 25, 2026 Becton Dickinson & Co. Announces Tender Offer Results: A Strategic Move in Debt Management Becton Dickinson & Co. announced the results of its $2 billion tender offers to repurchase various senior notes and debentures. This strategic move aims to optimize capital structure and reduce interest obligations, reflecting BD's proactive stance in managing debt amid market changes.
February 25, 2026 Becton Dickinson & Co. Announces Early Tender Results and Upsizing of Offer Becton Dickinson has announced the early results of its tender offers, increasing the total offer cap to $2 billion. This strategic move aims to manage debt effectively and improve financial health, with significant amounts already tendered by investors.
February 23, 2026 Becton Dickinson & Co Announces Upcoming Presentation at Barclays Healthcare Conference Becton Dickinson & Co will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The presentation will be available via live webcast, highlighting BD's commitment to healthcare innovation and investor engagement.
February 23, 2026 BD Expands Testing Capabilities to Enhance Diagnostic Accuracy BD has launched the Vacutainer® Urine Complete Cup Kit, aiming to improve diagnostic accuracy in urine testing. This innovative kit features a three-tube system that reduces contamination risks and enhances workflow efficiency, supporting better patient management.
February 19, 2026 Becton Dickinson & Co. Appoints Lanesha Minnix as General Counsel Becton Dickinson has appointed Lanesha Minnix as General Counsel, effective March 16, 2026. With extensive experience in corporate law, she aims to strengthen BD's legal framework and support innovation in healthcare.
February 10, 2026 Becton Dickinson & Co Announces Major Tender Offers for Outstanding Debt Securities Becton Dickinson has launched tender offers to repurchase up to $1.6 billion in outstanding debt securities. This strategic move aims to optimize the company's capital structure, with specific details on acceptance priorities and payment timelines outlined for investors.
February 09, 2026 BD Completes Strategic Spin-off and Merger with Waters Corporation BD has completed its spin-off of the Biosciences & Diagnostic Solutions business, merging with Waters Corporation. This strategic move positions BD as a focused medical technology leader, enhancing its capabilities in healthcare innovation while aligning with its 2025 strategy.
February 09, 2026 BD Reports Strong First Quarter Fiscal 2026 Financial Results BD announced impressive financial results for Q1 2026, showcasing a 1.6% revenue increase and significant strategic milestones, including innovative product launches and partnerships. CEO Tom Polen emphasized the company's commitment to growth and shareholder value, anticipating continued success in the evolving medical technology landscape.
February 09, 2026 Becton Dickinson & Co. Reports Strong Q1 Results for 2026: Navigating Challenges and Embracing Opportunities Becton Dickinson reported strong Q1 2026 results with $5.252 billion in revenue, a 1.6% increase year-over-year. The company restructured its operations into five segments to enhance efficiency and navigate challenges, focusing on growth opportunities despite regulatory hurdles.
January 29, 2026 Becton Dickinson & Co and Envetec Launch Innovative Recycling Initiative for Healthcare Plastics Becton Dickinson and Envetec have partnered to create a closed-loop recycling initiative for healthcare plastics. Their pilot study successfully demonstrated recycling polystyrene Petri dishes into new feedstock, paving the way for sustainable practices in the medical industry.
January 27, 2026 Becton Dickinson & Co. Declares Dividend and Expands Share Repurchase Program Becton Dickinson & Co. has declared a quarterly dividend of $1.05 and expanded its share repurchase program, aiming to enhance shareholder value. These moves reflect the company's strong financial strategy and commitment to innovation in the medical technology sector.
January 27, 2026 BD Set to Reveal First Quarter Financial Results for Fiscal 2026 Becton, Dickinson and Company (BD) will host an audio webcast on February 9, 2026, to discuss its Q1 financial results for fiscal 2026. Investors can access the live event and subsequent materials through BD's investor relations website, reinforcing the company's commitment to transparency.
January 27, 2026 BD Announces Key Steps in Spin-Off Strategy: A Focus on Biosciences and Diagnostic Solutions BD has announced a spin-off of its Biosciences & Diagnostic Solutions business, with a record date set for February 5, 2026. This move is part of a merger with Waters Corporation, aiming to improve shareholder value and operational focus. The transaction is expected to finalize on February 9, 2026, following regulatory approvals.
January 23, 2026 BD Unveils AI-Powered Insights to Enhance Immunology and Cancer Research BD® Research Cloud 7.0 introduces AI-powered tools like the BD Horizon™ Panel Maker, enhancing research efficiency in immunology and cancer studies. This innovative platform automates panel design, reduces complexity, and promises to improve scientific outcomes significantly.
January 21, 2026 BD and Ypsomed Strengthen Partnership to Tap into Biologics Market BD and Ypsomed have expanded their collaboration to develop a 5.5 mL prefillable syringe, responding to the increasing demand for biologics. This innovative syringe will enhance self-injection for patients, addressing challenges with large-volume medications and improving delivery efficiency.
January 15, 2026 BD Achieves FDA 510(k) Clearance for Innovative Breast Biopsy System BD has received FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy System, set to launch in early 2026. This innovative system enhances breast health diagnostics with multi-modality capabilities, optimized sample acquisition, and improved visualization, marking a significant advancement in patient care.
January 14, 2026 Becton Dickinson Appoints Shawn Bevec as Senior Vice President of Investor Relations Becton Dickinson has appointed Shawn Bevec as its new Senior Vice President of Investor Relations, effective January 20, 2026. With extensive experience in investor communications, Bevec aims to articulate BD's growth strategy and enhance shareholder engagement as the company continues to innovate in the medical technology sector.
January 13, 2026 BD Announces $110 Million Investment to Bolster U.S. Pharmaceutical Supply Chain BD has announced a $110 million investment to expand its prefillable syringe production in Columbus, Nebraska, creating 120 jobs. This move aims to strengthen the U.S. pharmaceutical supply chain and support biopharmaceutical innovations.
January 12, 2026 Becton Dickinson & Co. Announces Virtual Annual Meeting for 2026 Becton Dickinson & Co. will hold its virtual Annual Meeting for shareholders on January 27, 2026. This online format allows for broader participation and engagement with company executives. A replay will be available post-meeting for stakeholders.
January 05, 2026 Becton Dickinson & Co. Achieves Milestone in Hernia Prevention Becton Dickinson has achieved a major milestone with the first use of Phasix™ Mesh for hernia prevention in Greece. This advancement follows the product's EU approval and aims to reduce the incidence of incisional hernias, potentially saving healthcare costs.
December 18, 2025 BD Partners with Penn Institute to Propel Immunotherapy Research Becton, Dickinson and Company (BD) has partnered with the University of Pennsylvania's Institute for Immunology and Immune Health to advance immunotherapy research. This collaboration aims to develop a high-parameter flow cytometry panel and conduct an immune profiling study with 1,000 patients, leveraging BD's advanced technologies.
December 15, 2025 BD Expands Diagnostic Offerings with New VIASURE Assays BD has launched two new VIASURE assays for the BD MAX™ System, enhancing its diagnostic capabilities for respiratory viruses and STIs. This expansion, developed with Certest Biotec, underscores BD's commitment to innovation in healthcare diagnostics.
December 04, 2025 BD and ChemoGLO™ Join Forces to Enhance Safety in Healthcare Facilities BD has teamed up with ChemoGLO™ to enhance hazardous drug contamination testing in healthcare facilities. This collaboration combines rapid testing with advanced analysis, ensuring worker safety and compliance with industry standards. Learn more about their innovative approach at the upcoming ASHP Midyear Clinical Meeting.
December 03, 2025 BD Unveils Innovative Cell Analyzer Configurations to Empower Research Labs BD has launched new configurations of its FACSDiscover™ A8 Cell Analyzers, featuring advanced spectral imaging technologies that empower laboratories in various fields. These innovations aim to democratize access to high-end research tools, making significant contributions to immunology, cancer research, and cell biology.
November 25, 2025 Becton Dickinson & Co. Reports Robust Financial Performance for Fiscal Year 2025 Becton Dickinson & Co. reported impressive financial results for 2025, with $21.84 billion in revenue, an 8.2% increase from the previous year. The company plans to reorganize into five segments to enhance efficiency and market reach, while facing legal challenges amidst its growth.
November 24, 2025 BD Launches Surgiphor™ Surgical Wound Irrigation System in Europe BD has launched the Surgiphor™ Surgical Wound Irrigation System in Europe, aiming to reduce Surgical Site Infections and enhance surgical care. This innovative system features a ready-to-use solution, an antiseptic preservative, and a user-friendly design to improve operational efficiency and patient safety.
November 17, 2025 BD Strengthens Board with New Appointments Becton, Dickinson and Company has appointed Robert Huffines and Jacqueline Wright to its Board of Directors, effective December 1, 2025. Their extensive backgrounds in healthcare finance and technology will support BD's strategy for innovation and shareholder value.
November 17, 2025 BD Onclarity™ HPV Assay Achieves WHO Prequalification: A Milestone for Cervical Cancer Screening BD's Onclarity™ HPV Assay has achieved WHO prequalification, a key milestone that enhances cervical cancer screening access and improves detection capabilities. This advancement focuses on low- and middle-income countries, promoting self-collection methods and effective testing systems to combat cervical cancer.
November 13, 2025 Duncan Regional Hospital Leads the Way in EMR Infusion Interoperability Duncan Regional Hospital becomes the first U.S. hospital to implement BD Alaris™ EMR interoperability with MEDITECH, enhancing patient safety and operational efficiency. This integration automates medication administration, allowing healthcare professionals to focus more on patient care.
November 12, 2025 BD Expands PureWick™ Portfolio with Innovative Portable Solution for Urinary Incontinence BD has launched the PureWick™ Portable Collection System, a solution for urinary incontinence designed for wheelchair users. This innovative device enhances mobility, promotes independence, and offers discreet management of a common health issue.
November 06, 2025 Becton Dickinson & Co Reports Strong Financial Results for Fiscal 2025 Becton Dickinson & Co reported impressive financial results for fiscal 2025, with a 3.9% organic growth and total Q4 revenues of $5.89 billion. The company emphasizes its commitment to innovation and strategic partnerships as it looks to future growth.
November 06, 2025 Becton Dickinson & Co. Announces 54th Consecutive Dividend Increase Becton Dickinson & Co. has declared a 1.0% increase in its quarterly dividend, marking the 54th consecutive year of growth. This decision highlights the company's commitment to shareholder value amid ongoing corporate changes and its leadership in medical technology.
November 04, 2025 Becton Dickinson Achieves Key Milestone in AGILITY Study for Revello™ Stent Becton Dickinson has achieved full enrollment of the iliac artery cohort in its AGILITY study for the Revello™ Vascular Covered Stent, aimed at treating peripheral artery disease. This advancement highlights BD's commitment to innovating healthcare solutions for millions affected by PAD.
November 03, 2025 Becton Dickinson & Co. Receives FDA and CE Clearance for Enteric Bacterial Panels Becton Dickinson & Co. has received FDA and CE clearance for its Enteric Bacterial Panels, designed for rapid detection of GI pathogens. This innovation allows for quicker diagnosis and targeted treatment, addressing a critical public health need.
October 22, 2025 BD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States BD has introduced a revolutionary self-collection solution for HPV testing, aimed at expanding cervical cancer screening accessibility worldwide. This IVDR-certified method enhances laboratory efficiency and allows patients to collect samples safely at home.
October 20, 2025 BD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings BD has launched the BD Incada™ Connected Care Platform, integrating data across devices to enhance healthcare operations. Coupled with the BD Pyxis™ Pro, these solutions aim to improve medication management and clinical efficiency through advanced AI analytics.
October 16, 2025 BD Celebrates 65 Years of Manufacturing Excellence in Broken Bow, NE Becton, Dickinson and Company (BD) celebrates 65 years of excellence at its Broken Bow facility, the world's largest manufacturer of Vacutainer® tubes. With significant investments in U.S. manufacturing and community initiatives, BD emphasizes its commitment to innovation and quality healthcare.
October 15, 2025 Becton Dickinson & Co Announces CFO Transition and Preliminary Financial Results Becton Dickinson has announced a CFO transition with Chris DelOrefice departing and Vitor Roque stepping in as interim CFO. The company also reported preliminary fiscal 2025 revenue growth, highlighting challenges and opportunities in the evolving healthcare landscape.
October 09, 2025 BD Set to Announce Fourth Quarter and Full Year Fiscal Results for 2025 Becton, Dickinson and Company is set to announce its financial results for Q4 and FY 2025 on November 6, 2025. An audio webcast will provide insights into the company's operational performance and strategic initiatives. The announcement highlights BD's commitment to improving global healthcare.
October 09, 2025 BD Achieves Milestone in Peripheral Artery Disease Treatment with XTRACT™ Registry Becton, Dickinson and Company (BD) has enrolled its first patient in the XTRACT™ Registry, a study evaluating the Rotarex™ Catheter System for peripheral artery disease. The registry aims to gather real-world data to enhance treatment strategies and improve patient outcomes. With plans to enroll up to 600 patients, this initiative underscores BD's commitment to advancing PAD care.
October 08, 2025 BD and Opentrons Join Forces to Revolutionize Single-Cell Multiomics with Automation BD and Opentrons have formed a strategic collaboration to integrate robotics into single-cell multiomics, enhancing research efficiency and scalability. This partnership aims to automate critical processes, potentially transforming oncology and immunology studies.
October 03, 2025 BD Celebrates 55 Years of Manufacturing Excellence in Sumter, S.C. Becton, Dickinson and Company (BD) celebrates 55 years at its Sumter, SC facility, highlighting significant growth and community support. With over $90 million invested since 2021, BD is committed to enhancing its manufacturing capabilities and local contributions.
September 22, 2025 BD and Henry Ford Health Forge Innovative Pharmacy Automation Partnership BD has partnered with Henry Ford Health to launch the BD Rowa™ Vmax, a robotic pharmacy solution aimed at improving medication access and efficiency. This initiative promises 24/7 access to prescriptions and a streamlined pharmacy experience for patients.
September 17, 2025 BD Reaches Milestone with 1,000th Rhapsody System Installation BD has installed its 1,000th Rhapsody™ System, marking a significant milestone in single-cell multiomics. This advanced technology supports innovative research, particularly in understanding immune cell signaling pathways. The system's impact is reflected in over 700 peer-reviewed publications since its launch.
September 02, 2025 BD Expands Peripheral Artery Disease Awareness with New Initiative Becton, Dickinson and Company (BD) has launched the Love Your Limbs™ initiative to promote awareness of Peripheral Artery Disease (PAD) during PAD Awareness Month. The program offers free screenings and aims to address care disparities, emphasizing the importance of early detection to prevent serious health complications.
August 14, 2025 Becton Dickinson & Co Announces Participation in Wells Fargo 2025 Healthcare Conference Becton Dickinson & Co. will participate in the Wells Fargo 2025 Healthcare Conference on September 3, 2025, showcasing its latest healthcare innovations. The event will be accessible via live webcast, emphasizing BD's commitment to improving healthcare outcomes globally.
August 07, 2025 Becton Dickinson & Co Reports Strong Q3 Results and Strategic Merger Becton Dickinson's Q3 results reveal a 10.4% revenue increase to $5.51 billion and a strategic merger with Waters Corporation. The company focuses on innovation and operational efficiency to enhance its market position.
August 07, 2025 Becton Dickinson & Co. Reports Strong Q3 2025 Results Amid Strategic Changes Becton Dickinson reported a strong Q3 2025 with $5.509 billion in revenue, reflecting a 10.4% increase. Key strategic initiatives, including a merger with Waters Corporation, aim to enhance its market position in life sciences and diagnostics.
August 05, 2025 Becton, Dickinson and Company Achieves Historic Supply Chain Resilience Recognition Becton, Dickinson and Company has made history by being the first in the MedTech industry to receive a diamond-level rating for supply chain resilience across all domains. This recognition highlights BD's dedication to ensuring timely and efficient access to critical medical supplies for healthcare providers worldwide.
August 04, 2025 BD Expands Manufacturing to Strengthen U.S. Healthcare Resilience Becton, Dickinson and Company (BD) is investing over $35 million to expand its Nebraska facility, creating 50 jobs and increasing production of prefilled flush syringes. This move aims to strengthen the U.S. healthcare system and meet surging demand for essential medical devices.
July 31, 2025 BD Revolutionizes Cervical Cancer Screening with New At-Home HPV Test BD has submitted a new at-home HPV test application to the FDA, allowing women to self-collect samples easily for cervical cancer screening. This innovation promises to enhance accessibility and comfort, reporting more high-risk HPV strains than any current product.
July 30, 2025 Becton Dickinson & Co. Secures FDA Clearance for Rapid COVID-19 Test Becton Dickinson & Co. has received FDA 510(k) clearance for its BD Veritor™ System, allowing rapid COVID-19 testing in various healthcare settings. This innovative test delivers results in about 15 minutes, enhancing diagnostic capabilities and improving patient outcomes.
July 23, 2025 BD Launches Groundbreaking Clinical Trial for Wearable Injector Technology BD has initiated a clinical trial for the Libertas™ Wearable Injector, designed for easy self-administration of biologics. With strong pre-clinical results and a commitment to innovation, this technology promises to improve patient compliance and access to therapies.
July 22, 2025 BD Board Declares Quarterly Dividend Amid Strong Financial Performance Becton, Dickinson and Company (BD) has declared a quarterly dividend of $1.04 per share, payable on September 30, 2025. This announcement reflects BD's strong financial performance and commitment to shareholder returns, while the company continues to innovate in the medical technology sector.
July 07, 2025 Becton Dickinson Appoints Bilal Muhsin as EVP and President of Future Connected Care Segment Becton Dickinson appoints Bilal Muhsin as EVP and President of Future Connected Care, focusing on advanced analytics and AI to revolutionize patient care. His extensive experience in health technology positions BD for significant growth in the MedTech sector.
May 28, 2025 BD Launches Innovative Registry to Enhance Outcomes for Patients with Peripheral Artery Disease BD has initiated the XTRACT Registry to evaluate the Rotarex™ Atherectomy System's effectiveness in treating peripheral artery disease. Enrolling 600 patients across 100 sites, this study aims to enhance clinical practices and improve patient outcomes in PAD management.
May 27, 2025 Becton Dickinson & Co Set to Present at Goldman Sachs Healthcare Conference Becton Dickinson will present at the Goldman Sachs Healthcare Conference on June 9, 2025. The company emphasizes its commitment to innovation and healthcare advancements, which will be highlighted during the live webcast accessible via their investor relations website.
May 21, 2025 Becton Dickinson & Co Highlights Urgent Need for Action Against Antimicrobial Resistant 'Superbugs' in Cancer Patients Becton Dickinson & Co's recent studies show that cancer patients face significantly higher risks of antimicrobial resistant infections. The findings call for urgent action in infection prevention and antibiotic stewardship to safeguard vulnerable patients.
May 13, 2025 BD Unveils Revolutionary Cell Analyzer to Transform Research Landscape BD has launched the FACSDiscover™ A8 Cell Analyzer, a groundbreaking device that combines advanced imaging technologies for enhanced cell analysis. This innovation supports researchers in biomarker discovery and translational research, promising significant advancements in healthcare outcomes.
May 12, 2025 BD to Announce Third Quarter Financial Results for Fiscal 2025 Becton, Dickinson and Company (BD) will announce its third quarter financial results for FY 2025 on August 7, 2025, during a live audio webcast. The event will provide insights into BD's performance and strategic direction, reflecting its ongoing commitment to healthcare innovation.
May 01, 2025 Becton Dickinson & Co Reports Solid Q2 2025 Results Amidst Challenging Environment Becton Dickinson achieved a 4.5% revenue increase to $5.27 billion in Q2 2025, despite a challenging environment. The company plans to invest $2.5 billion in U.S. manufacturing to bolster its leadership in medical technology.
May 01, 2025 Becton Dickinson Reports Strong Q2 2025 Results Amid Strategic Changes Becton Dickinson's Q2 2025 financial results show a 4.5% revenue increase to $5.272 billion, despite a decline in net income. The company plans a strategic separation of its Biosciences and Diagnostic Solutions business to enhance focus and drive growth.
April 30, 2025 Becton Dickinson & Co to Present at Bank of America Securities Health Care Conference Becton Dickinson & Co will present at the Bank of America Securities Health Care Conference on May 13, 2025. The company aims to highlight its advancements in healthcare solutions and commitment to improving patient outcomes through innovative technologies.
April 29, 2025 Becton Dickinson & Co Declares Quarterly Dividend Amidst Strong Market Position Becton Dickinson & Co has declared a quarterly dividend of $1.04 per share, highlighting its strong financial position and commitment to shareholder value. This decision showcases BD’s leadership in medical technology and its ongoing focus on innovation and global health partnerships.
April 23, 2025 BD Launches Groundbreaking Bioabsorbable Mesh for Hernia Repair BD has launched the Phasix™ ST Umbilical Hernia Patch, the first fully absorbable patch for umbilical hernias, receiving FDA clearance. This innovative product meets the growing demand for non-permanent mesh solutions, providing surgeons with effective options for patient care.
April 21, 2025 BD Launches Revolutionary HemoSphere Alta™ for Enhanced Hemodynamic Monitoring BD has launched the HemoSphere Alta™, an advanced hemodynamic monitoring platform utilizing AI for improved blood flow management. Key features include the Cerebral Autoregulation Index and predictive capabilities to enhance patient care during critical procedures.
April 03, 2025 BD Set to Unveil Second Quarter Financial Results for Fiscal 2025 Becton, Dickinson and Company will host an audio webcast on May 1, 2025, to discuss its Q2 financial results and operational updates. The webcast will provide critical insights into BD's performance and commitment to improving healthcare globally.
March 31, 2025 Becton Dickinson & Co Recognized as One of America’s Most Innovative Companies Becton Dickinson & Co. has been named one of America's Most Innovative Companies by Fortune for 2025, ranking in the top 25%. CEO Tom Polen emphasizes the company's dedication to continuous improvement and innovation in medical technology to meet global healthcare needs.
March 27, 2025 Gregory J. Hayes Joins Becton Dickinson's Board of Directors Becton Dickinson has appointed Gregory J. Hayes to its board, aiming to boost shareholder value and transform its operations. Hayes brings extensive experience from RTX and United Technologies, promising to drive innovation and operational excellence for the company.
March 20, 2025 BD Marks a Significant Milestone in Breast Surgery Innovation with GalaFLEX LITE™ Scaffold Clinical Trial BD has initiated a pivotal clinical trial for the GalaFLEX LITE™ Scaffold, designed to reduce capsular contracture in breast implant revisions. This innovative approach aims to enhance patient outcomes and transform breast surgery practices.
March 06, 2025 SWOT Analysis of Becton Dickinson & Co in 2025 This article provides a SWOT analysis of Becton Dickinson & Co, highlighting its strong market position and innovative capabilities, while also addressing key challenges and opportunities in the healthcare sector for 2025.
February 13, 2025 BD to Showcase Innovations at Upcoming Healthcare Conferences Becton, Dickinson and Company (BD) will showcase its innovations at the Citi 2025 Unplugged Medtech Conference and the Barclays Global Healthcare Conference. These events highlight BD's commitment to enhancing healthcare delivery through technology and innovation.
February 06, 2025 Becton Dickinson & Co. Reports Strong Q1 2025 Financial Results Becton Dickinson & Co. announced a 9.8% revenue increase for Q1 2025, totaling $5.168 billion. The company is focused on innovation and strategic growth, despite facing regulatory challenges and rising expenses.
February 05, 2025 BD Announces Strategic Separation to Unlock Value and Drive Growth BD is set to undergo a strategic separation, creating two distinct entities: New BD focused on medical technology and a standalone Biosciences and Diagnostic Solutions segment. This move aims to enhance capital allocation and innovation, with both entities poised for significant growth in their respective markets.
February 05, 2025 Becton Dickinson & Co Reports Strong First Quarter Results for Fiscal 2025 Becton Dickinson's first quarter of fiscal 2025 saw significant revenue growth, with total revenues reaching $5.168 billion, a 9.8% increase from the previous year. The company is focused on innovation and has updated its fiscal outlook, reflecting strong operational performance and strategic initiatives including a stock repurchase program.
November 27, 2024 Becton Dickinson & Co. Reports Strong Financial Performance for 2024 Becton Dickinson & Co. reported a solid financial performance for 2024, with revenues reaching $20.178 billion, a 4.2% increase. The company emphasized growth through strategic acquisitions and innovations, despite facing global market challenges.
August 01, 2024 Becton Dickinson & Co. Reports Strong Q3 2024 Results Becton Dickinson & Co. reports a solid Q3 2024 with $4.99 billion in revenue, a 2.3% year-over-year increase. The company's growth is attributed to strong demand in key segments and a strategic acquisition set to enhance its market position.
May 02, 2024 Becton Dickinson & Co. Reports Strong Q2 2024 Financial Results Becton Dickinson & Co. reported a 4.6% increase in Q2 2024 revenues, driven by strong demand in key product categories. The company navigates regulatory challenges while maintaining a solid cash flow position.
